As a first step, metabolomic profiles were compared between IDH-mutant gliomas and IDH-wt gliomas regardless of histological subtype and grade in order to identify which metabolites were preferentially produced in each molecular pathway. This evidence concerns the gene IDH2 and central nervous system cancer.